Treatment-Emergent Adverse Events (TEAEs) with Oxymetazoline

[Guide]

A new acronym, TEAE [Treatment-Emergent Adverse Events], has been published in the June issue of the Journal of the American Academy of Dermatology,  in an article entitled, "Sustained Use of Oxymetazoline Cream Efficacious for Rosacea," according to MPR, about a study on the long-term safety (1 year) and efficacy of oxymetazoline cream 1.0% in 440 patients with rosacea spear headed by Zoe Diana Draelos, MD, who volunteers on the RRDi MAC. The study concluded:

"This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea."

"The rate of discontinuation mostly due to application-site TEAEs was 3.2%"

So the TEAE is low with oxymetazoline treatment for rosacea.